0.25Open0.25Pre Close0 Volume1 Open Interest30.00Strike Price0.00Turnover0.00%IV38.20%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.25Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma192.56Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Bentley Systems Stock Discussion
$Fortinet (FTNT.US)$ : “Fortinet reported a very good quarter...I remain committed to Nikesh Arora and Palo Alto Networks, which I think is doing the best of all of them.”
$Enova (ENVA.US)$ : “Enova, a little dicey. A little dicey because it’s untraditional lending...
Gap Ups
1. $Fair Isaac (FICO.US)$ - up 15.95%
2. $NICE Ltd (NICE.US)$ - up 15.35%
3. $BILL Holdings (BILL.US)$ - up 8.69%
4. $Datadog (DDOG.US)$ - up 7.05%
5. $Coupang (CPNG.US)$ - up 6.21%
6. $Match group (MTCH.US)$ - up 5.98%
7. $Zscaler (ZS.US)$ - up 5.97%
8. $ServiceNow (NOW.US)$ - up 5...
• $Banco De Chile (BCH.US)$ : Santander Upgrades to Outperform from Neutral - PT $25
• $Comerica (CMA.US)$ : Baird Upgrades to Outperform from Neutral - PT $85
• $Mirati Therapeutics (MRTX.US)$ : Guggenheim Upgrades to Buy from Neutral - PT $115
• $Ollie's Bargain Outlet (OLLI.US)$ : BofA Securities Upgrades to Buy from Underperform - PT $75 (from $39)
• $Trex Co. (TREX.US)$ : Exane Upgrades to Neutral from Underperform - PT $75
Downgrades
• $Ferguson (FERG.US)$ : Exane D...
The Post Labor Day IPO storm is coming this week and several large IPOs will be listed.
On the last trading day, there was one traditional IPO filed and one new stock officially listed for trading.
MiNK Therapeutics, founded in 2017, is a Phase 1 biotech developing allogenic T cell therapies for cancer and immune-mediated diseases.
MiNK Therapeutics' lead program, AGENT-797, is an allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapy targeting cancer and other immune-mediated diseases. The company claims that iNKT cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host disease. AGENT-797 is currently conducting a Phase 1 trial in multiple myeloma patients that is expected to report top-line data in the fourth quarter of 2021.
$Sportradar Group AG (SRAD.US)$ , founded in 2001, is a sports betting and data firm. It provides mission-critical software, data and content via subscription, and revenue share arrangements to betting operators, sports leagues, and media companies.
Sportradar offers robust and fully integrated sports data and technology platforms. It serves as a critical data infrastructure and content layer to the sports betting and media industries. On top of that infrastructure layer, it has built advanced and comprehensive software offerings.
Sportradar leads on the breadth of events coverage for sports data and odds. It collects over 1.2 billion live data points per year from over 600,000 events in 37 sports.
Related:
IPO-pedia: Sports betting and data firm Sportradar plans New York IPO
$Bentley Systems (BSY.US)$ is a software development company that supports the professional needs of those responsible for creating and managing the world’s infrastructure, including roadways, bridges, airports, skyscrapers, and industrial and power plants, as well as utility networks.
Bentley delivers solutions for the entire lifecycle of the infrastructure asset, tailored to the needs of the various professions – the engineers, architects, geospatial professionals, planners, contractors, fabricators, IT managers, operators and maintenance engineers – who will work on and work with that asset over its lifetime.
As of September 15th, it has a market cap of $19.48 billion, with the listed to date gain of 214.32%.
No comment yet